Metastasis Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-Resistant Prostate Cancer

被引：0
|
作者：
Deek, M. P. [1 ]
Taparra, K. [2 ]
Phillips, R. [1 ]
Velho, P. Isaacsson [1 ]
Gao, R. W. [3 ]
Deville, C., Jr. [1 ]
Song, D. [4 ]
Greco, S. C. [4 ]
Carducci, M. [1 ]
Eisenberger, M. [1 ]
DeWeese, T. L. [4 ]
Denmeade, S. [1 ]
Pienta, K. [5 ]
Paller, C. [1 ]
Antonarakis, E. S. [1 ]
Olivier, K. [6 ]
Park, S. S. [6 ]
Tran, P. T. [4 ]
Stish, B. J. [6 ]
机构：
[1] Johns Hopkins Med, Baltimore, MD USA
[2] Mayo Clin, Alix Sch Med, Rochester, MN USA
[3] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[4] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Med Oncol, Baltimore, MD USA
[6] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 108卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4079
引用
收藏
页码：E893 / E894
页数：2
相关论文
共 50 条
  • [41] Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
    Lam, Hung-Ming
    Corey, Eva
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [42] Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer
    Nakabayashi, Mari
    Werner, Lillian
    Oh, William K.
    Regan, Meredith M.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    CLINICAL GENITOURINARY CANCER, 2011, 9 (02) : 95 - 103
  • [43] Second line therapy for castration-resistant prostate cancer (CRPC)
    Molitor, B.
    Boergermann, C.
    UROLOGE, 2012, 51 (03): : 357 - 362
  • [44] Current possibilities of drug therapy for castration-resistant prostate cancer
    Markova, A. S.
    ONKOUROLOGIYA, 2013, 9 (02): : 73 - 77
  • [45] Wnt signaling in castration-resistant prostate cancer: implications for therapy
    Yokoyama, Noriko N.
    Shao, Shujuan
    Hoang, Bang H.
    Mercola, Dan
    Zi, Xiaolin
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2014, 2 (01): : 27 - 44
  • [46] Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy
    Soichiro Yoshida
    Taro Takahara
    Yuki Arita
    Kazuma Toda
    Ichiro Yamada
    Hajime Tanaka
    Minato Yokoyama
    Yoh Matsuoka
    Ryoichi Yoshimura
    Yasuhisa Fujii
    International Urology and Nephrology, 2021, 53 : 1119 - 1125
  • [47] Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy
    Yoshida, Soichiro
    Takahara, Taro
    Arita, Yuki
    Toda, Kazuma
    Yamada, Ichiro
    Tanaka, Hajime
    Yokoyama, Minato
    Matsuoka, Yoh
    Yoshimura, Ryoichi
    Fujii, Yasuhisa
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (06) : 1119 - 1125
  • [48] Treatment-Refractory, Castration-Resistant Prostate Cancer With Liver Metastasis: A Promising Modality of Therapy
    Findakly, Dawood
    Duong, Tony
    Shimon, Tim
    Wang, Jue
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
  • [49] Sequential therapy of castration-resistant prostate cancer: Evidence-based clinical algorithms
    Peres, Tobias
    Omlin, Aurelius
    AKTUELLE UROLOGIE, 2024, 55 (02) : 161 - 173
  • [50] A case of repeat oligoprogressive castration-resistant prostate cancer treated with pulmonary metastasectomy
    Soma, Takahiko
    Yoshida, Soichiro
    Wakejima, Ryo
    Taguchi, Towako
    Fukuda, Shohei
    Tanaka, Hajime
    Yokoyama, Minato
    Ohashi, Kenichi
    Okubo, Kenichi
    Fujii, Yasuhisa
    IJU CASE REPORTS, 2023, 6 (04) : 216 - 218
12345